regulatory is the most under-discussed thing in c/vendorvetting
sequence. That is the whole post, but I will justify it. Everything else people worry about in c/labresults is downstream of it. Titration speed, early fullness, the endless dose arguments — most of it resolves if you sort sequence out first, and almost nobody does. I say this having got it wrong for 22 months. My…
What are you comparing it against though?
regulatory status changed in 23 countries, check yours
Removed a chain here. The rule is one line long and it is not negotiable.
the tendon literature looks promising but rodent-only
the pentadecapeptide rodent evidence is solid, human evidence is not
regulatory status changed in 5 countries, check yours
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
regulatory status changed in 7 countries, check yours